Effect of Maridebart Cafraglutide on the Heart's Electrical Activity
← catalyst calendarNCT07229157 · readout in 7 d
Sponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Basic science
Enrollment
81actual
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-22 | actual | When the study began enrolling |
| Primary completion | 2026-08-26 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-08-26 | estimated | The whole study's end, after follow-up |
| First posted | 2025-11-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Overweight
- Obesity
Interventions
- Drug: Maridebart Cafraglutide — also filed as AMG 133
- Drug: Moxifloxacin
- Drug: Placebo for Maridebart Cafraglutide
- Drug: Placebo for Moxifloxacin
Primary outcome
what the primary-completion date above is the date OFChange from Baseline in QTcF for Maridebart Cafraglutide
measured Up to Day 171
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed